Phenylbutazone
As of the edition of 20 October 2026, Phenylbutazone is a small molecule: marketed, first approved in 1971 (ES); acts on PTGS1 and PTGS2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Butazolidin
- First approved
- 1 October 1971 (ES)
- Approvals on record
- 3 in 2 regions
- Holder of the most recent approval
- Novartis; 2 holders in all
- Withdrawn from market
- 1 January 1984 (in some regions)
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route B because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of Phenylbutazone.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Novartis | Acquired holder | 2003 to now |
| GEIGY Pharmaceuticals | Earlier holder |